Electrochemotherapy for Breast Cancer: Results From the INSPECT Database

Louise Wichmann Matthiessen; Mohammed Keshtgar; Pietro Curatolo; Christian Kunte; Eva-Maria Grischke; Joy Odili; Tobian Muir; David Mowatt; James P Clover; Se Hwang Liew; Karin Dahlstroem; Jackie Newby; Valerie Letulé; Eva Stauss; Alison Humphreys; Shramana Banerjee; Annette Klein; Roberta Rotunno; Francesca de Terlizzi; Julie Gehl

doi:10.1016/j.clbc.2018.03.007

Electrochemotherapy for Breast Cancer: Results From the INSPECT Database

Louise Wichmann Matthiessen, Mohammed Keshtgar, Pietro Curatolo, Christian Kunte, Eva-Maria Grischke, Joy Odili, Tobian Muir, David Mowatt, James P Clover, Se Hwang Liew, Karin Dahlstroem, Jackie Newby, Valerie Letulé, Eva Stauss, Alison Humphreys, Shramana Banerjee, Annette Klein, Roberta Rotunno, Francesca de Terlizzi, Julie Gehl

Department of Clinical Medicine

20 Citations (Scopus)

Abstract

Electrochemotherapy is a palliative treatment for patients with cutaneous metastases and provides symptomatic relief for these patients. Here are results for breast cancer patients included in the International Network for Sharing Practice on ElectroChemoTherapy database. It shows that electrochemotherapy is a safe and efficient treatment with few side effects. We therefore recommend considering electrochemotherapy for patients with cutaneous metastases. Background: Cutaneous recurrence from breast cancer can pose a clinical challenge. It might be the only disease site, or could be part of disseminated disease, and often profoundly affects quality of life. Electrochemotherapy is a palliative treatment using electric pulses to locally permeabilize tumor cells and thereby significantly increase bleomycin cytotoxicity. Collaborating with the International Network for Sharing Practice on ElectroChemoTherapy (INSPECT), we consecutively and prospectively accrued data on patients treated with electrochemotherapy for cutaneous metastases from breast cancer. Patients and Methods: Patients were treated with electrochemotherapy at 10 European centers. Under either local or general anaesthesia patients were treated with either local injection (1000 IU/mL intratumoral) or systemic infusion (15,000 IU/m ² ) of bleomycin. Results: One hundred nineteen patients were included at 10 institutions in the INSPECT network. The primary location was the chest (89%), the median diameter of the cutaneous metastases was 25 mm. Ninety patients were available for response evaluation after 2 months. Complete response was observed in 45 patients (50%), partial response in 19 (21%), stable disease in 16 (18%), and progressive disease in 7 (8%). Three patients were not evaluable. Common side effects were ulceration, long-lasting hyperpigmentation, and low-grade pain. No serious adverse events were observed. Conclusion: Electrochemotherapy showed high response rates after a single treatment. Electrochemotherapy has few side effects and can be used as an adjunct to systemic therapies or as a solo treatment. We therefore recommend considering electrochemotherapy for patients with cutaneous metastases.

Original language	English
Journal	Clinical Breast Cancer
Volume	18
Issue number	5
Pages (from-to)	e909-e917
ISSN	1526-8209
DOIs	https://doi.org/10.1016/j.clbc.2018.03.007
Publication status	Published - Oct 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clbc.2018.03.007

Cite this

Matthiessen, L. W., Keshtgar, M., Curatolo, P., Kunte, C., Grischke, E.-M., Odili, J., Muir, T., Mowatt, D., Clover, J. P., Liew, S. H., Dahlstroem, K., Newby, J., Letulé, V., Stauss, E., Humphreys, A., Banerjee, S., Klein, A., Rotunno, R., de Terlizzi, F., & Gehl, J. (2018). Electrochemotherapy for Breast Cancer: Results From the INSPECT Database. Clinical Breast Cancer, 18(5), e909-e917. https://doi.org/10.1016/j.clbc.2018.03.007

Matthiessen, LW, Keshtgar, M, Curatolo, P, Kunte, C, Grischke, E-M, Odili, J, Muir, T, Mowatt, D, Clover, JP, Liew, SH, Dahlstroem, K, Newby, J, Letulé, V, Stauss, E, Humphreys, A, Banerjee, S, Klein, A, Rotunno, R, de Terlizzi, F & Gehl, J 2018, 'Electrochemotherapy for Breast Cancer: Results From the INSPECT Database', Clinical Breast Cancer, vol. 18, no. 5, pp. e909-e917. https://doi.org/10.1016/j.clbc.2018.03.007

@article{5a54c2e94fc74c38820176e769b7e0d0,

title = "Electrochemotherapy for Breast Cancer: Results From the INSPECT Database",

abstract = " Electrochemotherapy is a palliative treatment for patients with cutaneous metastases and provides symptomatic relief for these patients. Here are results for breast cancer patients included in the International Network for Sharing Practice on ElectroChemoTherapy database. It shows that electrochemotherapy is a safe and efficient treatment with few side effects. We therefore recommend considering electrochemotherapy for patients with cutaneous metastases. Background: Cutaneous recurrence from breast cancer can pose a clinical challenge. It might be the only disease site, or could be part of disseminated disease, and often profoundly affects quality of life. Electrochemotherapy is a palliative treatment using electric pulses to locally permeabilize tumor cells and thereby significantly increase bleomycin cytotoxicity. Collaborating with the International Network for Sharing Practice on ElectroChemoTherapy (INSPECT), we consecutively and prospectively accrued data on patients treated with electrochemotherapy for cutaneous metastases from breast cancer. Patients and Methods: Patients were treated with electrochemotherapy at 10 European centers. Under either local or general anaesthesia patients were treated with either local injection (1000 IU/mL intratumoral) or systemic infusion (15,000 IU/m 2 ) of bleomycin. Results: One hundred nineteen patients were included at 10 institutions in the INSPECT network. The primary location was the chest (89%), the median diameter of the cutaneous metastases was 25 mm. Ninety patients were available for response evaluation after 2 months. Complete response was observed in 45 patients (50%), partial response in 19 (21%), stable disease in 16 (18%), and progressive disease in 7 (8%). Three patients were not evaluable. Common side effects were ulceration, long-lasting hyperpigmentation, and low-grade pain. No serious adverse events were observed. Conclusion: Electrochemotherapy showed high response rates after a single treatment. Electrochemotherapy has few side effects and can be used as an adjunct to systemic therapies or as a solo treatment. We therefore recommend considering electrochemotherapy for patients with cutaneous metastases. ",

author = "Matthiessen, {Louise Wichmann} and Mohammed Keshtgar and Pietro Curatolo and Christian Kunte and Eva-Maria Grischke and Joy Odili and Tobian Muir and David Mowatt and Clover, {James P} and Liew, {Se Hwang} and Karin Dahlstroem and Jackie Newby and Valerie Letul{\'e} and Eva Stauss and Alison Humphreys and Shramana Banerjee and Annette Klein and Roberta Rotunno and {de Terlizzi}, Francesca and Julie Gehl",

year = "2018",

month = oct,

doi = "10.1016/j.clbc.2018.03.007",

language = "English",

volume = "18",

pages = "e909--e917",

journal = "Clinical Breast Cancer",

issn = "1526-8209",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Electrochemotherapy for Breast Cancer

T2 - Results From the INSPECT Database

AU - Matthiessen, Louise Wichmann

AU - Keshtgar, Mohammed

AU - Curatolo, Pietro

AU - Kunte, Christian

AU - Grischke, Eva-Maria

AU - Odili, Joy

AU - Muir, Tobian

AU - Mowatt, David

AU - Clover, James P

AU - Liew, Se Hwang

AU - Dahlstroem, Karin

AU - Newby, Jackie

AU - Letulé, Valerie

AU - Stauss, Eva

AU - Humphreys, Alison

AU - Banerjee, Shramana

AU - Klein, Annette

AU - Rotunno, Roberta

AU - de Terlizzi, Francesca

AU - Gehl, Julie

PY - 2018/10

Y1 - 2018/10

N2 - Electrochemotherapy is a palliative treatment for patients with cutaneous metastases and provides symptomatic relief for these patients. Here are results for breast cancer patients included in the International Network for Sharing Practice on ElectroChemoTherapy database. It shows that electrochemotherapy is a safe and efficient treatment with few side effects. We therefore recommend considering electrochemotherapy for patients with cutaneous metastases. Background: Cutaneous recurrence from breast cancer can pose a clinical challenge. It might be the only disease site, or could be part of disseminated disease, and often profoundly affects quality of life. Electrochemotherapy is a palliative treatment using electric pulses to locally permeabilize tumor cells and thereby significantly increase bleomycin cytotoxicity. Collaborating with the International Network for Sharing Practice on ElectroChemoTherapy (INSPECT), we consecutively and prospectively accrued data on patients treated with electrochemotherapy for cutaneous metastases from breast cancer. Patients and Methods: Patients were treated with electrochemotherapy at 10 European centers. Under either local or general anaesthesia patients were treated with either local injection (1000 IU/mL intratumoral) or systemic infusion (15,000 IU/m 2 ) of bleomycin. Results: One hundred nineteen patients were included at 10 institutions in the INSPECT network. The primary location was the chest (89%), the median diameter of the cutaneous metastases was 25 mm. Ninety patients were available for response evaluation after 2 months. Complete response was observed in 45 patients (50%), partial response in 19 (21%), stable disease in 16 (18%), and progressive disease in 7 (8%). Three patients were not evaluable. Common side effects were ulceration, long-lasting hyperpigmentation, and low-grade pain. No serious adverse events were observed. Conclusion: Electrochemotherapy showed high response rates after a single treatment. Electrochemotherapy has few side effects and can be used as an adjunct to systemic therapies or as a solo treatment. We therefore recommend considering electrochemotherapy for patients with cutaneous metastases.

AB - Electrochemotherapy is a palliative treatment for patients with cutaneous metastases and provides symptomatic relief for these patients. Here are results for breast cancer patients included in the International Network for Sharing Practice on ElectroChemoTherapy database. It shows that electrochemotherapy is a safe and efficient treatment with few side effects. We therefore recommend considering electrochemotherapy for patients with cutaneous metastases. Background: Cutaneous recurrence from breast cancer can pose a clinical challenge. It might be the only disease site, or could be part of disseminated disease, and often profoundly affects quality of life. Electrochemotherapy is a palliative treatment using electric pulses to locally permeabilize tumor cells and thereby significantly increase bleomycin cytotoxicity. Collaborating with the International Network for Sharing Practice on ElectroChemoTherapy (INSPECT), we consecutively and prospectively accrued data on patients treated with electrochemotherapy for cutaneous metastases from breast cancer. Patients and Methods: Patients were treated with electrochemotherapy at 10 European centers. Under either local or general anaesthesia patients were treated with either local injection (1000 IU/mL intratumoral) or systemic infusion (15,000 IU/m 2 ) of bleomycin. Results: One hundred nineteen patients were included at 10 institutions in the INSPECT network. The primary location was the chest (89%), the median diameter of the cutaneous metastases was 25 mm. Ninety patients were available for response evaluation after 2 months. Complete response was observed in 45 patients (50%), partial response in 19 (21%), stable disease in 16 (18%), and progressive disease in 7 (8%). Three patients were not evaluable. Common side effects were ulceration, long-lasting hyperpigmentation, and low-grade pain. No serious adverse events were observed. Conclusion: Electrochemotherapy showed high response rates after a single treatment. Electrochemotherapy has few side effects and can be used as an adjunct to systemic therapies or as a solo treatment. We therefore recommend considering electrochemotherapy for patients with cutaneous metastases.

U2 - 10.1016/j.clbc.2018.03.007

DO - 10.1016/j.clbc.2018.03.007

M3 - Journal article

C2 - 29673795

SN - 1526-8209

VL - 18

SP - e909-e917

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

IS - 5

ER -

Electrochemotherapy for Breast Cancer: Results From the INSPECT Database

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this